These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21076446)

  • 1. Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin?
    Borghi L; Nouvenne A; Meschi T
    Kidney Int; 2010 Dec; 78(11):1063-5. PubMed ID: 21076446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.
    Lieske JC; Tremaine WJ; De Simone C; O'Connor HM; Li X; Bergstralh EJ; Goldfarb DS
    Kidney Int; 2010 Dec; 78(11):1178-85. PubMed ID: 20736987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.
    Assimos D
    J Urol; 2011 Feb; 185(2):549-50. PubMed ID: 22088636
    [No Abstract]   [Full Text] [Related]  

  • 4. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.
    Noori N; Honarkar E; Goldfarb DS; Kalantar-Zadeh K; Taheri M; Shakhssalim N; Parvin M; Basiri A
    Am J Kidney Dis; 2014 Mar; 63(3):456-63. PubMed ID: 24560157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gut microbiota against calcium oxalate.
    Sadaf H; Raza SI; Hassan SW
    Microb Pathog; 2017 Aug; 109():287-291. PubMed ID: 28624518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperoxaluria in idiopathic calcium oxalate nephrolithiasis.
    Yendt ER
    Md Med J; 1988 Nov; 37(11):857-60. PubMed ID: 3185157
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of a probiotic to decrease enteric hyperoxaluria.
    Lieske JC; Goldfarb DS; De Simone C; Regnier C
    Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study.
    Nouvenne A; Meschi T; Guerra A; Allegri F; Prati B; Fiaccadori E; Maggiore U; Borghi L
    Urology; 2009 Apr; 73(4):725-30, 730.e1. PubMed ID: 19193409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones.
    Khan SR
    Scanning Microsc; 1995 Mar; 9(1):89-100; discussion 100-1. PubMed ID: 8553028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenesis of hyperoxalurias and calcium oxalate calculi in intestinal diseases].
    Müller G; Schütte W; Möller T
    Dtsch Z Verdau Stoffwechselkr; 1987; 47(3):105-12. PubMed ID: 3311705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperoxaluric calcium nephrolithiasis.
    Asplin JR
    Endocrinol Metab Clin North Am; 2002 Dec; 31(4):927-49. PubMed ID: 12474639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
    Abratt VR; Reid SJ
    Adv Appl Microbiol; 2010; 72():63-87. PubMed ID: 20602988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperoxaluria in patients with idiopathic calcium nephrolithiasis.
    Trinchieri A; Ostini F; Nespoli R; Rovera F; Zanetti G; Pisani E
    J Nephrol; 1998; 11 Suppl 1():70-2. PubMed ID: 9604817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What treatments reduce kidney stone risk in patients with bowel disease?
    Bianco J; Chu F; Bergsland K; Coe F; Worcester E; Prochaska M
    Urolithiasis; 2022 Oct; 50(5):557-565. PubMed ID: 35976425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of patients with enteric hyperoxaluria.
    Asplin JR
    Urolithiasis; 2016 Feb; 44(1):33-43. PubMed ID: 26645872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
    Langman CB; Grujic D; Pease RM; Easter L; Nezzer J; Margolin A; Brettman L
    Am J Nephrol; 2016; 44(2):150-8. PubMed ID: 27529510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of hyperoxaluria-induced kidney dysfunction by chemical chaperone 4-phenylbutyric acid.
    Randhawa R; Bhardwaj R; Kaur T
    Urolithiasis; 2019 Apr; 47(2):171-179. PubMed ID: 29947992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dietary interventions on 24-hour urine parameters in patients with idiopathic recurrent calcium oxalate stones.
    Kıraç M; Küpeli B; Irkilata L; Gülbahar O; Aksakal N; Karaoğlan U; Bozkırlı I
    Kaohsiung J Med Sci; 2013 Feb; 29(2):88-92. PubMed ID: 23347810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diet and nephrolithiasis.
    Goldfarb S
    Annu Rev Med; 1994; 45():235-43. PubMed ID: 8198380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diet and renal stone formation.
    Trinchieri A
    Minerva Med; 2013 Feb; 104(1):41-54. PubMed ID: 23392537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.